Abstract
Febrile neutropenia (FN) is a major complication in patients with diffuse large B-Cell lymphoma (DLBCL). Diabetes mellitus (DM) has deleterious effects on the immune system resulting in an increased risk of infections. We evaluated patients with DLBCL who started frontline treatment with R-CHOP, and compared outcomes according to presence of DM comorbidity. Between 2013 and 2018, 218 patients with DLBCL were included. 46 patients (21%) had DM. Rate of admissions for FN was higher for patients with DM (0.7 vs. 0.46 admissions/patient, p =.016), also after age and gender-matched subgroup analysis (p =.004). Improved glycemic control during FN hospitalizations was associated with shorter hospitalizations. Metformin was associated with improved median overall survival in diabetic patients (89 vs. 64 months, p =.018). In conclusion, Patients with DLBCL and DM had higher rates of FN hospitalizations. Improved glycemic control during FN hospitalization was associated with shorter length of stay.
Original language | English (US) |
---|---|
Pages (from-to) | 3378-3384 |
Number of pages | 7 |
Journal | Leukemia and Lymphoma |
Volume | 63 |
Issue number | 14 |
DOIs | |
State | Published - 2022 |
Externally published | Yes |
Keywords
- diabetes mellitus
- Diffuse large B cell lymphoma
- Febrile neutropenia
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research